Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($0.54), $0.12 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $71.04 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $316.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.